Anagrelide
Term · Oncology and biomedicine · MLC-T-ONC-000484
A drug that is used to decrease the number of platelets in the blood in order to prevent blood clotting.
A synthetic quinazoline derivative, anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis.
| Identifier | MLC-T-ONC-000484 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-000484",
"term": "Anagrelide",
"field": "Oncology and biomedicine",
"definitions": [
"A drug that is used to decrease the number of platelets in the blood in order to prevent blood clotting.",
"A synthetic quinazoline derivative, anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis."
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anagrelide/"
}
Record 1,027 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.